Age-related Macular Degeneration AMD Drugs Market Demand Driven by Rising Prevalence Advancements in Anti VEGF Therapies and Dry AMD Treatment Expansion

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Report By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User (Hospitals, Specialty Centers, Long-Term Care Facilities)- Market Outlook And Industry Analysis 2031"

The Global Age-related Macular Degeneration (AMD) Drugs Market is valued at US$ 9.58 Bn in 2023, and it is expected to reach US$ 19.77 Bn by 2031, with a CAGR of 9.7% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2854

Age-related Macular Degeneration (AMD) is a progressively debilitating ocular condition primarily affecting the elderly population, characterized by the deterioration of the macula-the central region of the retina responsible for sharp, detailed vision. AMD is classified into two primary forms: dry AMD, the more prevalent type, which progresses gradually and leads to a slow decline in vision, and wet AMD, marked by rapid vision loss due to the development of abnormal blood vessels beneath the retina.

The AMD drugs market is currently dominated by anti-VEGF (vascular endothelial growth factor) therapies, including well-established treatments such as Eylea and Lucentis, which are primarily used in the management of wet AMD. These therapies work by inhibiting the formation of new, abnormal blood vessels that contribute to vision impairment. More recently, the emergence of advanced therapeutics such as Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) has introduced promising treatment options for dry AMD-particularly in cases involving geographic atrophy-a segment that has historically been underserved.

The value of AMD therapies lies in their ability to slow disease progression and preserve visual function. Market growth is being driven by several factors, including the aging global population, increasing prevalence of AMD due to lifestyle and environmental influences, and continued innovation in ophthalmologic research. The introduction of novel treatment options for dry AMD represents a significant advancement, offering improved clinical outcomes and enhanced quality of life for patients. These developments underscore the expanding potential of the AMD drugs market to meet the evolving needs of a growing patient demographic.

List of Prominent Players in the Age-related Macular Degeneration (AMD) Drugs Market:
• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche AG (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals, Inc. (US)
• Coherus BioSciences, Inc. (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG (Germany)
• Formycon AG (Germany)
• Biocon. (India)
• Outlook Therapeutics, Inc. (US)
• Intas Pharmaceuticals Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chengdu Kanghong Biotech Company (China)
• Sandoz Group AG (Switzerland)
• Stealth BioTherapeutics Inc. (US)
• Ocular Therapeutix, Inc. (US)
• Opthea Limited, Inc. (Australia)
• Kodiak Sciences Inc. (US)
• Innovent Biologics, Inc. (China)
• Bio-Thera Solution Inc. (China)
• Alvotech (Iceland)
• Alteogen Inc. (South Korea)
• Shanghai Henlius Biotech, Inc. (China)
• Amgen Inc. (US)
• Ocumension Therapeutics. (China)
• Adverum Biotechnologies, Inc. (US)

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The Age-related Macular Degeneration (AMD) drugs market is experiencing robust growth, underpinned by several key factors. The global rise in AMD prevalence-particularly among aging populations-is being driven by lifestyle-related risk factors such as poor dietary habits, smoking, and physical inactivity. Advancements in drug development, including the introduction of innovative therapies like Pegcetacoplan (Syfovre) and Avacincaptad Pegol (IZERVAY) for dry AMD, as well as extended-duration anti-VEGF treatments for wet AMD, have expanded treatment options and improved therapeutic efficacy.

Enhanced reimbursement frameworks have increased treatment accessibility, fostering greater adherence to prescribed regimens. Additionally, emerging markets in the Asia-Pacific and Latin America regions present new avenues for expansion, supported by increased investment in research and development. The growing emphasis on personalized medicine and the rise of public-private collaborations are also playing a pivotal role in driving innovation and aligning treatment approaches with individual patient needs-ultimately contributing to improved satisfaction, outcomes, and market growth.

Challenges:
Despite these positive trends, several challenges persist within the AMD drugs market. The high cost of treatment-particularly in the case of branded anti-VEGF therapies such as Eylea and Vabysmo-remains a significant barrier to access and adherence, prompting some patients to opt for off-label alternatives due to cost concerns. Moreover, dry AMD has historically been underserved, with limited pharmacological options available and reliance on dietary supplements in place of approved medications, thereby restricting market potential.

Regional Trends:
North America currently dominates the AMD drugs market, supported by a strong pharmaceutical research and development ecosystem and the presence of leading industry players and academic institutions. The region benefits from substantial R&D investment, facilitating the rapid development and approval of new treatments, such as biosimilars like Enzeevu for wet AMD. A well-established healthcare infrastructure equipped with advanced diagnostic and treatment capabilities contributes to early intervention and high-quality care. Furthermore, a supportive regulatory environment-highlighted by the proactive stance of the U.S. FDA in approving novel therapies-continues to accelerate market advancement. Favorable reimbursement structures and active public-private partnerships further enhance access to treatment, promote innovation, and improve patient outcomes, reinforcing the region's leadership in the global AMD market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2854

Recent Developments:
• In August 2023, Regeneron Pharmaceuticals announced that the U.S. FDA has approved EYLEA HD (aflibercept) 8 mg for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
• In March 2022, Novartis announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for treating visual impairment due to diabetic macular edema (DME), marking its second EC-approved indication following wet age-related macular degeneration in 2020.

Segmentation of Age-related Macular Degeneration (AMD) Drugs Market-
By Products:
• Lucentis
• Eylea & Eylea HD
• Vabysmo
• Syfovre
• Other Products
By Molecules:
• Ranibizumab
• Aflibercept
• Faricimab
• Pegcetoplan
• Other Molecules
By Type of AMD:
• Wet AMD
• Dry AMD
By Approval type:
• Biologic
• Biosimilar
By End User:
• Hospitals
• Specialty Centers
• Long-Term Care Facilities
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.